The Federal Trade Commission is preparing to sue the largest three pharmacy-benefit managers over their tactics for negotiating prices for drugs including insulin, after a two-year investigation into whether the companies steer patients away from less-expensive medicines.
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/20/2026 | $1350.00 | Overweight | Barclays | |
| 1/7/2026 | $1250.00 | Buy | UBS | |
| 12/16/2025 | $1230.00 | Neutral → Buy | Daiwa Securities | |
| 12/15/2025 | $951.00 → $1145.00 | Buy | Goldman | |
| 12/15/2025 | $1286.00 → $1268.00 | Buy | BofA Securities | |
| 11/13/2025 | $1165.00 | Sector Outperform | Scotiabank | |
| 11/10/2025 | $1104.00 | Market Perform → Outperform | Leerink Partners | |
| 10/20/2025 | $840.00 → $930.00 | Outperform | BMO Capital Markets |
Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00
UBS resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $1,250.00
Daiwa Securities upgraded Eli Lilly from Neutral to Buy and set a new price target of $1,230.00
The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar
Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's diseaseINDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE:LLY) showed Omvoh (mirikizuma
Building on its relationship with the Washington Spirit, CVS expands its commitment to soccer through a new multi-year sponsorship with the league and federation, which includes a national community field investment and partnering with the Kansas City Current and Seattle Reign FCWOONSOCKET, R.I., Feb. 19, 2026 /PRNewswire/ -- CVS Pharmacy® has furthered its commitment to improving community health by becoming an Official Health and Wellness Partner of the U.S. Soccer Federation (USSF) and the National Women's Soccer League (NWSL) and is backing that sponsorship with a multi-year investment to develop community multi‑use soccer fields in select markets across the country.
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - Cigna Group (0001739940) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell
Corporate, Nonprofit, and Philanthropic Partners Collaborated to Provide Transformative Experiences and Lasting Resources at Burckhalter Elementary School OAKLAND, Calif., Feb. 3, 2026 /PRNewswire/ -- Vincent Country Safe Zone Activity Day Presented by Cigna Healthcare, a flagship initiative of Love Thy Neighbor CDC co-founded by NFL Executive and Legend Troy Vincent, Sr. and his wife, author and chef Tommi A. Vincent, took place Tuesday, February 3, at Burckhalter Elementary School in Oakland, CA. The ninth annual event, themed Dreams Grow Here, delivered a full day of fun, food, wellness, and engaging sports activities, including NFL FLAG, for more than 200 Pre-K through fifth-grade studen
INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an
SC 13G - CVS HEALTH Corp (0000064803) (Subject)
SC 13G - Cigna Group (0001739940) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
Fourth Quarter Highlights Total revenues increased to $105.7 billion, up 8.2% compared to prior yearGAAP diluted EPS of $2.30 and Adjusted EPS of $1.09Full-Year Highlights Total revenues increased to a record high $402.1 billion, up 7.8% compared to prior yearGAAP diluted EPS of $1.39 and Adjusted EPS of $6.75Generated cash flow from operations of $10.6 billionOperational Highlights CVS Pharmacy® successfully completed the transition to cost-based reimbursement across its Commercial, Third-Party Discount, Medicare and Medicaid businesses.Aetna® continues to improve the experience for health care professionals and their patients, approving more than 95% of all eligible prior authorizations wi
Total revenues for 2025 increased 11% to $274.9 billionShareholders' net income for 2025 was $6.0 billion, or $22.18 per shareAdjusted income from operations1 for 2025 was $8.0 billion, or $29.84 per share2026 adjusted income from operations1 is projected to be at least $7.950 billion, or at least $30.25 per share2Board of Directors declared an increase in the quarterly dividend to $1.56 per shareBLOOMFIELD, Conn., Feb. 5, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported 2025 results, underscoring operational discipline and the strength of its complimentary portfolio of global health businesses.
Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in
13F-HR - CVS HEALTH Corp (0000064803) (Filer)
10-K - ELI LILLY & Co (0000059478) (Filer)
10-K - CVS HEALTH Corp (0000064803) (Filer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)